Concurrently, the amylin analogue pramlintide was shown to improve cognitive impairment in AD, suggesting that administration of exogenous amylin-type peptides have the potential to become a new therapeutic avenue for AD [31]. This evidence concerns the gene IAPP and Alzheimer disease.